Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,712 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia Clear all
Completed Phase 1Phase 2 Interventional Results available

Kuvan in People With Schizophrenia and Schizoaffective Disorder

NCT01706965
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Kuvan, Multivitamin
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 64 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 19, 2026, 11:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Transcranial Direct Current Stimulation (tDCS) and Cognitive Processing

NCT01602263
View directory record Official record
Conditions
Aphasia, Autism, Schizophrenia
Interventions
Transcranial Direct Current Stimulation (tDCS)
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 79 Years
Enrollment
307 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 19, 2026, 11:37 PM EDT
Completed Not applicable Interventional Results available

Home-based Transcranial Direct Current Stimulation (tDCS) for Behavioral Symptoms in Alzheimer's Disease and Related Dementias (ADRD)

NCT05478681
View directory record Official record
Conditions
Alzheimer Disease
Interventions
active tDCS
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
60 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 19, 2026, 11:37 PM EDT
Completed Not applicable Interventional

A Novel Person-Centered Treatment Component for Substance Use Treatment

NCT02005367
View directory record Official record
Conditions
Substance Use Disorders, Depression, Bipolar Disorder, Psychosis, Personality Disorders
Interventions
Natural Recovery-Horticulture, Natural Recovery-Art/Music
Behavioral
Lead sponsor
Hampton VA Medical Center
Federal
Eligibility
18 Years to 85 Years
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Hampton, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Oct 19, 2026, 11:37 PM EDT
Completed Phase 3 Interventional

Effectiveness of a Lifestyle Intervention for Increasing Physical Activity in Adults With Schizophrenia

NCT00338832
View directory record Official record
Conditions
Schizophrenia
Interventions
Physically Ready for Invigorating Movement Every Day (PRIME), Program for Activity, Leisure Skills, and Socialization (PALSS)
Behavioral
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
21 Years to 64 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2013 · Synced Oct 19, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

Biomarkers in Schizophrenia

NCT00817336
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
D Serine, Placebo
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Oct 19, 2026, 11:37 PM EDT
Completed Not applicable Interventional

Graduated Recovery Intervention Program for Enhancing Treatment for First-Episode Psychosis

NCT00307216
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia
Interventions
Graduated Recovery Intervention Program (GRIP), Treatment as usual (TAU)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 19, 2026, 11:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CSC OnDemand: An Innovative Online Learning Platform for Implementing Coordinated Specialty Care

NCT02933567
View directory record Official record
Conditions
Psychosis
Interventions
CSC OnDemand
Other
Lead sponsor
Center for Social Innovation, Massachusetts
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 19, 2026, 11:37 PM EDT
Completed Not applicable Interventional

DMHI for At-Risk College Students

NCT06608498
View directory record Official record
Conditions
Prodromal Symptoms, Psychosis
Interventions
SPARK Coping
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 30 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 19, 2026, 11:37 PM EDT
Completed Not applicable Interventional

Can Neural Network Instability in Schizophrenia be Improved With a Very Low Carbohydrate Ketogenic Diet?

NCT05268809
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
Ketogenic diet
Other
Lead sponsor
Northern California Institute of Research and Education
Other
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 19, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Results available

Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder

NCT01423916
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
OPC-34712 (4mg), Moxifloxacin, OPC-34712 (12mg), Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
8
States / cities
Long Beach, California • San Diego, California • Fort Lauderdale, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Oct 19, 2026, 11:37 PM EDT
Completed Not applicable Interventional

Neuromodulation of Social Cognitive Circuitry in People With Schizophrenia Spectrum Disorders

NCT04418011
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
Interventions
Repetitive Transcranial Magnetic Stimulation, Repetitive Transcranial Magnetic Stimulation (Intermittent Theta Burst Stimulation), Repetitive Transcranial Magnetic Stimulation (Sham)
Device
Lead sponsor
Centre for Addiction and Mental Health
Other
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Catonsville, Maryland • Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 19, 2026, 11:37 PM EDT
Not listed Not applicable Interventional

Cognitive Remediation in Supported Employment at Human Service Center (HSC)

NCT00138021
View directory record Official record
Conditions
Vocational Rehabilitation, Schizophrenia, Mental Disorders, Cognitive Symptoms
Interventions
Computerized cognitive training program
Device
Lead sponsor
Human Service Center, Illinois
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 2, 2007 · Synced Oct 19, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective

NCT02504476
View directory record Official record
Conditions
Schizophrenia or Schizoaffective Disorder
Interventions
AMG 581, Placebo, Midazolam
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Oct 19, 2026, 11:37 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Effects of Nicotine Withdrawal on Reward Responsivity in Schizophrenia

NCT00373126
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
transdermal nicotine patch
Drug
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2009 · Synced Oct 19, 2026, 11:37 PM EDT
Not listed Phase 4 Interventional

Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia

NCT02282085
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole Once-Monthly, Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)
Drug
Lead sponsor
Matt Byerly
Other
Eligibility
18 Years to 60 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 19, 2026, 11:37 PM EDT
Completed Phase 4 Interventional

Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder

NCT00100776
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Olanzapine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
33
States / cities
Anaheim, California • National City, California • Orange, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2007 · Synced Oct 19, 2026, 11:37 PM EDT
Completed Phase 1 Interventional

Social Cognitive Training for Psychosis: Treatment Development

NCT01579422
View directory record Official record
Conditions
Schizophrenia, Psychosis
Interventions
social cognitive training
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Oct 19, 2026, 11:37 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.

NCT01122927
View directory record Official record
Conditions
Adolescent Schizophrenia, Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
23
States / cities
Dothan, Alabama • Downey, California • Miami, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 19, 2026, 11:37 PM EDT
Completed Not applicable Interventional Results available

Vitamin D Supplementation in Psychiatric Illnesses

NCT01004354
View directory record Official record
Conditions
Obesity, Vitamin D Deficiency, Psychosis, Schizophrenia, Schizoaffective Disorder
Interventions
Ergocalciferols
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
10 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 19, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)

NCT03565068
View directory record Official record
Conditions
Schizophrenia
Interventions
MK-8189, Placebo, Background AAP Therapy
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 19, 2026, 11:37 PM EDT
Completed Not applicable Interventional

Is Cognitive Training an Option?

NCT05352568
View directory record Official record
Conditions
Schizophrenia, Schizoaffective, Cognition
Interventions
Cognitive Training
Behavioral
Lead sponsor
Alliant International University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 19, 2026, 11:37 PM EDT
Completed Phase 1 Interventional

Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics

NCT02037074
View directory record Official record
Conditions
Schizophrenia
Interventions
Drug: EVP-6308, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2015 · Synced Oct 19, 2026, 11:37 PM EDT
Completed Phase 1 Interventional

Bio-equivalence Study Between SAPHRIS and Asenapine

NCT01948024
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
SAPHRIS, Asenapine
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
7
States / cities
Little Rock, Arkansas • Costa Mesa, California • Garden Grove, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 19, 2026, 11:37 PM EDT